<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973827</url>
  </required_header>
  <id_info>
    <org_study_id>ProTrans-Repeat</org_study_id>
    <secondary_id>2018-004158-11</secondary_id>
    <nct_id>NCT03973827</nct_id>
  </id_info>
  <brief_title>Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes</brief_title>
  <official_title>An Open Label, Parallel Single Center Trial of Wharton's Jelly Derived Allogeneic Mesenchymal Stromal Cells Repeatedly Treated to Preserve Endogenous Insulin Production in Adult Patients Diagnosed With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NextCell Pharma Ab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NextCell Pharma Ab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, parallel single centre trial of Wharton's Jelly derived allogenic mesenchymal&#xD;
      stromal cells repeated treatment to preserve endogenous insulin production in adult patients&#xD;
      diagnosed with type 1 diabetes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">October 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions</measure>
    <time_frame>372 days</time_frame>
    <description>To investigate the safety and tolerance after a repeated allogeneic infusion of Whartons Jelly Mesenchymal Stromal Cells (WJMSCs) intravenously in adult patients diagnosed with type 1 diabetes after one year following the repeated treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.</measure>
    <time_frame>372 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients insulin independent (ADA criteria) at day 372.</measure>
    <time_frame>372 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with daily insulin needs &lt;0.25U/kg at day 372.</measure>
    <time_frame>372 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at day 372</measure>
    <time_frame>372 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372</measure>
    <time_frame>372 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment</measure>
    <time_frame>372 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients with peak C-peptide &gt;0.20 nmol/l, in response to the MMTT, at day 372.</measure>
    <time_frame>372 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>ProTrans-Repeat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 1-3: 25 x10e6 cells Patients 4-6:100 x10e6 cells Patients 7-9:200 x10e6 cells&#xD;
Control group 9 patients= non treated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ProTrans</intervention_name>
    <description>ProTrans is an pooled allogenic mesenchymal stromal cell treatment</description>
    <arm_group_label>ProTrans-Repeat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A new written informed consent for participation of the study is required to be given&#xD;
             before undergoing any study-specific procedures.&#xD;
&#xD;
          2. Only patients that have previously been dosed by the IMP according to protocol&#xD;
             Protrans-1 are eligible for a second dose of Protrans.&#xD;
&#xD;
          3. No identified IMP related on-going adverse event, neither history of any adverse event&#xD;
             that is evaluated potentially to be related to the previous IMP dosing in Protrans I.&#xD;
&#xD;
          4. Clinical history compatible with type 1 diabetes diagnosed less than 3 years before&#xD;
             enrolment. This also includes control patients not receiving IMP.&#xD;
&#xD;
          5. Only male patients between 18-41 years of age will be included.&#xD;
&#xD;
          6. Mentally stable and, in the opinion of the investigator, able to comply with the&#xD;
             procedures of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Patients with body mass index (BMI) &gt; 30, or weight &gt;100 kg&#xD;
&#xD;
          3. Patients with weight &lt;50 kg&#xD;
&#xD;
          4. Patients with unstable cardiovascular status incl. NYHA class III/IV or symptoms of&#xD;
             angina pectoris.&#xD;
&#xD;
          5. Patients with uncontrolled hypertension (≥160/105 mmHg).&#xD;
&#xD;
          6. Patients with active infections unless treatment is not judged necessary by the&#xD;
             investigators&#xD;
&#xD;
          7. Patients with latent or previous as well as on-going therapy against tuberculosis, or&#xD;
             exposed to tuberculosis or has travelled in areas with high risk of tuberculosis or&#xD;
             mycosis within the last 3 months.&#xD;
&#xD;
          8. Patients with serological evidence of infection with HIV, Treponema pallidum,&#xD;
             hepatitis B antigen (patients with serology consistent with previous vaccination and a&#xD;
             history of vaccination are acceptable) or hepatitis C.&#xD;
&#xD;
          9. Patients with any immune suppressive treatment&#xD;
&#xD;
         10. Patients with known demyelinating disease or with symptoms or physical examination&#xD;
             findings consistent with possible demyelinating disease.&#xD;
&#xD;
         11. Patients with known, or previous, malignancy.&#xD;
&#xD;
         12. Taking oral anti-diabetic therapies or any other concomitant medication which may&#xD;
             interfere with glucose regulation other than insulin&#xD;
&#xD;
         13. Patients with GFR &lt;80 ml/min/1.73 m2 body surface&#xD;
&#xD;
         14. Patients with proliferative retinopathy&#xD;
&#xD;
         15. Patient with any condition or any circumstance that in the opinion of the investigator&#xD;
             would make it unsafe to undergo treatment with MSC.&#xD;
&#xD;
         16. Known hypersensitivity against any excipients, i.e. dimethyl sulfoxide (DMSO).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per-Ola Carlsson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathias SVAHN, PhD</last_name>
    <phone>+4687355595</phone>
    <email>mathias.svahn@nextcellpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leo Groenewegen</last_name>
    <phone>+4687355595</phone>
    <email>leogroenewegen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Sisay, PhD</last_name>
      <phone>+46(0)8-51771644</phone>
      <email>sofia.sisay@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>MSC's</keyword>
  <keyword>Mesenchymal</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Stromal</keyword>
  <keyword>Wharton´s Jelly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

